We are live on
!
Find out more
Squarepoint Portfolio holdings
AUM
$85.1B
1-Year Est. Return
20.93%
This Fund
S&P 500
This Quarter
Est. Return
+12.98%
1 Year Est. Return
+20.93%
3 Year Est. Return
+51.38%
5 Year Est. Return
+34.63%
10 Year Est. Return
+146.23%
AUM
$52.8B
AUM Growth
+$12.4B
(+31%)
Cap. Flow
+$6.6B
Cap. Flow
% of AUM
12.49%
Top 10 Holdings %
Top 10 Hldgs %
10.83%
Holding
4,679
New
953
Increased
1,510
Reduced
1,399
Closed
740
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$763M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$336M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$246M |
| 4 |
Apple
AAPL
|
+$203M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$139M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intuit
INTU
|
+$158M |
| 2 |
Sherwin-Williams
SHW
|
+$155M |
| 3 |
Goldman Sachs
GS
|
+$139M |
| 4 |
Bank of America
BAC
|
+$127M |
| 5 |
Royal Caribbean
RCL
|
+$126M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 9.3% |
| 2 | Consumer Discretionary | 7.9% |
| 3 | Healthcare | 4.86% |
| 4 | Financials | 4.75% |
| 5 | Industrials | 3.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TSVT
3751
DELISTED
2seventy bio
TSVT
| $98.9K | ﹤0.01% |
23,164
-28,527
| -55% | -$87.7K |
|
3752
Monte Rosa Therapeutics
GLUE
$1.92B
| $98.7K | ﹤0.01% |
+17,462
| New | +$68.5K |
|
3753
Riskified
RSKD
$672M
| $98.6K | ﹤0.01% |
21,071
-80,633
| -79% | -$330K |
|
3754
Cardio Diagnostics
CDIO
$4.59M
| $97.4K | ﹤0.01% |
+1,304
| New | +$45.1K |
|
|
SVC
3755
Service Properties Trust
SVC
$1.1B
| $96.4K | ﹤0.01% |
2,257
-5,084
| -69% | -$192K |
|
3756
Cogent Biosciences
COGT
$6.79B
| $95.7K | ﹤0.01% |
+16,277
| New | +$125K |
|
3757
Achieve Life Sciences
ACHV
$626M
| $95.2K | ﹤0.01% |
23,105
+10,631
| +85% | +$46.3K |
|
3758
PureCycle Technologies
PCT
$1.17B
| $95.1K | ﹤0.01% |
23,483
-212,697
| -90% | -$934K |
|
3759
Destination XL Group
DXLG
$34.7M
| $94.9K | ﹤0.01% |
21,557
-19,418
| -47% | -$83.2K |
|
3760
Tilray
TLRY
$479M
| $94.7K | ﹤0.01% |
4,118
+1,682
| +69% | +$32.4K |
|
3761
Babcock & Wilcox
BW
$1.43B
| $94.6K | ﹤0.01% |
64,772
-132,950
| -67% | -$283K |
|
3762
W&T Offshore
WTI
$545M
| $94.2K | ﹤0.01% |
28,892
-32,029
| -53% | -$118K |
|
|
WHWK
3763
Whitehawk Therapeutics
WHWK
$183M
| $93.3K | ﹤0.01% |
46,164
+22,565
| +96% | +$94.7K |
|
3764
Personalis
PSNL
$1.26B
| $92.8K | ﹤0.01% |
44,198
+31,899
| +259% | +$41.2K |
|
|
CTV
3765
DELISTED
Innovid Corp.
CTV
| $92.8K | ﹤0.01% |
61,853
-119,925
| -66% | -$153K |
|
3766
Fossil Group
FOSL
$239M
| $90.7K | ﹤0.01% |
62,125
+14,369
| +30% | +$21.1K |
|
3767
Bolt Biotherapeutics
BOLT
$7.36M
| $89.3K | ﹤0.01% |
3,989
-13
| -0.3% | -$253 |
|
|
NAGE
3768
Niagen Bioscience
NAGE
$256M
| $88.5K | ﹤0.01% |
61,899
+3,632
| +6% | +$5.06K |
|
3769
ARKO Corp
ARKO
$890M
| $88.4K | ﹤0.01% |
10,713
-48,973
| -82% | -$375K |
|
3770
Evolution Petroleum
EPM
$137M
| $88.2K | ﹤0.01% |
+15,182
| New | +$93K |
|
|
BZUN
3771
Baozun
BZUN
$144M
| $86.7K | ﹤0.01% |
31,630
-25,770
| -45% | -$75.9K |
|
3772
Energy Fuels
UUUU
$2.82B
| $85.4K | ﹤0.01% |
+11,881
| New | +$91.9K |
|
|
ASRT
3773
DELISTED
Assertio
ASRT
| $85.3K | ﹤0.01% |
5,317
-35,356
| -87% | -$874K |
|
3774
Lumen
LUMN
$6.53B
| $85.3K | ﹤0.01% |
46,603
-117,650
| -72% | -$167K |
|
|
ICD
3775
DELISTED
Independence Contract Drilling, Inc.
ICD
| $85K | ﹤0.01% |
34,710
+7,734
| +29% | +$19.9K |
|
Similar funds
Squarepoint's Q4 2023 Portfolio in Review
As of Q4 2023, Squarepoint held 4,679 positions worth $52.8B, up 31% from $40.5B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Squarepoint deployed $6.6B of net new capital in Q4 2023, opening 953 new positions and adding to 1,510 existing holdings. Its largest new stake was iShares Core S&P 500 ETF: 550,000 shares worth $263M.
By sector, the portfolio is most concentrated in Technology at 9.3% of assets, down from 11% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Intuit, an estimated $158M trimmed.
- Squarepoint's largest Q4 2023 buy was iShares Core S&P 500 ETF: 550,000 shares worth $263M.
- Squarepoint added most to State Street SPDR S&P 500 ETF Trust in Q4 2023, an estimated $763M increase.
- Squarepoint's biggest Q4 2023 reduction was Intuit, cutting an estimated $158M.
- Squarepoint fully exited State Street SPDR S&P MIDCAP 400 ETF Trust in Q4 2023, selling an estimated $97.9M.
- Squarepoint's ten largest holdings make up 11% of its $52.8B portfolio in Q4 2023.
- Squarepoint opened 953 new positions and closed 740 in Q4 2023.
- Squarepoint's portfolio value rose 31% quarter-over-quarter to $52.8B.
Based on Squarepoint's 13F filing for Q4 2023, filed 14 Feb 2024.